Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 3
Submit an article Journal homepage
693
Views
13
CrossRef citations to date
0
Altmetric
Original Articles: Research

Anti-tumor efficacy study of the Bruton’s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab

Tomoko YasuhiroOno Pharmaceutical Co, Ltd, Osaka, Japan;
,
Wako SawadaOno Pharmaceutical Co, Ltd, Osaka, Japan;
,
Christian KleinRoche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland
,
Ryohei KozakiOno Pharmaceutical Co, Ltd, Osaka, Japan;
,
Shingo HottaOno Pharmaceutical Co, Ltd, Osaka, Japan;
&
Toshio YoshizawaOno Pharmaceutical Co, Ltd, Osaka, Japan; Correspondence[email protected]
Pages 699-707 | Received 12 Feb 2016, Accepted 08 Jun 2016, Published online: 09 Aug 2016

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Rabih Said & Apostolia M. Tsimberidou. (2017) Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. Expert Opinion on Biological Therapy 17:11, pages 1463-1470.
Read now
Pawel Robak & Tadeusz Robak. (2017) Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 26:11, pages 1249-1265.
Read now
Christian Klein, Marina Bacac, Pablo Umana & Günter Fingerle-Rowson. (2017) Combination therapy with the type II anti-CD20 antibody obinutuzumab. Expert Opinion on Investigational Drugs 26:10, pages 1145-1162.
Read now

Articles from other publishers (10)

Hui Yu, Xing Wang, Jiao Li, Yingying Ye, Dedao Wang, Wei Fang, Lan Mi, Ning Ding, Xiaogan Wang, Yuqin Song & Jun Zhu. (2021) Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. Molecular Therapy - Oncolytics 21, pages 158-170.
Crossref
Yaya Chu, Aradhana Awasthi, Sanghoon Lee, Dina Edani, Changhong Yin, Jessica Hochberg, Tishi Shah, Tae-Hoon Chung, Janet Ayello, Carmella van de Ven, Christian Klein, Dean Lee & Mitchell S. Cairo. (2020) Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. Oncotarget 11:32, pages 3035-3047.
Crossref
Sohita Dhillon. (2020) Tirabrutinib: First Approval. Drugs 80:8, pages 835-840.
Crossref
Feifei Sun, Xiaosheng Fang & Xin Wang. (2020) Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma. Anti-Cancer Agents in Medicinal Chemistry 19:17, pages 2047-2059.
Crossref
Yuko Ariza, Masayuki Murata, Yoshiko Ueda & Toshio Yoshizawa. (2019) Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption. Bone Reports 10, pages 100201.
Crossref
Avick Kumar Ghosh, Indranil Samanta, Anushree Mondal & Wenshe Ray Liu. (2019) Covalent Inhibition in Drug Discovery. ChemMedChem 14:9, pages 889-906.
Crossref
Yaya Chu, Mitchell S. Cairo & Auke Beishuizen. 2019. Resistance to Targeted Therapies in Lymphomas. Resistance to Targeted Therapies in Lymphomas 111 153 .
Ryohei Kozaki, Meike Vogler, Harriet Walter, Sandrine Jayne, David Dinsdale, Reiner Siebert, Martin Dyer & Toshio Yoshizawa. (2018) Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. Cancers 10:4, pages 127.
Crossref
Anna Maria Frustaci, Alessandra Tedeschi, Marina Deodato, Maddalena Mazzucchelli, Roberto Cairoli & Marco Montillo. (2018) Ibrutinib and its use in the treatment of chronic lymphocytic leukemia. Future Oncology 14:8, pages 681-697.
Crossref
Floyd Hassenrück, Eva Knödgen, Elisa Göckeritz, Safi Hasan Midda, Verena Vondey, Lars Neumann, Sylvia Herter, Christian Klein, Michael Hallek & Günter Krause. (2018) Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway Inhibitors. BioMed Research International 2018, pages 1-9.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.